

Technology Advisory Committee C Interests Register

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]

Publication Date: 2 February 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Michael Chambers	Committee Member	Financial	Mr Michael Chambers has attended an advisory Board for Pfizer in an unrelated disease area.	N/A	17.08.2021	N/A	It was agreed that this declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
Ms Charlotte Martin	Patient expert	Direct – Non-Financial	Ms Charlotte Martin has been an employee of Leukaemia Care since June 2018.	N/A	11.02.2021	N/A	It was agreed that this declaration would not prevent Ms Martin from providing expert advice to the committee.
Dr Elspeth Payne	Clinical expert	Financial	Dr Elspeth Payne has received honoraria for talks and advisory boards from Celgene, a BMS company.	N/A	27.11.2020	N/A	It was agreed that this declaration would not prevent Dr Payne from providing expert advice to the committee.